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CBackground: The evidence base informing economic evaluation mod-
els is rarely derived from a single source. Researchers are typically
expected to identify and combine available data to inform the estima-
tion of model parameters for a particular decision problem. The
absence of clear guidelines on what data can be used and how to effec-
tively synthesize this evidence base under different scenarios inevita-
bly leads to different approaches being used by different modelers.
Objectives: The aim of this article is to produce a taxonomy that can
help modelers identify the most appropriate methods to use when
synthesizing the available data for a given model parameter.
Methods: This article developed a taxonomybased onpossible scenar-
ios faced by the analyst when dealing with the available evidence.
Whilemainly focusing on clinical effectiveness parameters, this article
also discusses strategies relevant to other key input parameters in any
economic model (i.e., disease natural history, resource use/costs, and
cono
onom
doi:10.1016/j.jval.2012.02.009references). Results: The taxonomy categorizes the evidence base for
ealth economic modeling according to whether 1) single or multiple
ata sources are available, 2) individual or aggregate data are available
or both), or 3) individual or multiple decision model parameters are to
e estimated from the data. References to examples of the key meth-
dological developments for each entry in the taxonomy together with
itations to where such methods have been used in practice are pro-
ided throughout.Conclusions: The use of the taxonomy developed in
his article hopes to improve the quality of the synthesis of evidence
nforming decision models by bringing to the attention of health eco-
omics modelers recent methodological developments in this field.
eywords: aggregate data, decision analytic models, economic
valuation, evidence synthesis, individual patient data, meta-analysis.
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Economic evaluations assess the costs and health consequences
of competing health care interventions, programs, or services.
Their aim is to inform policy decisions regarding resource provi-
sion within health care systems operating under a limited or fixed
budget.
The information required to carry out an economic evaluation
rarely comes froma single study [1].More commonly, the evidence
base informing the model parameters is represented by one or
more data sources, including individual patient-level data sets
(e.g., randomized controlled trials [RCTs] and observational stud-
ies), expert opinions, and secondary data analyses (e.g., meta-
analysis). Decision analytic models represent an ideal vehicle to
structure the decision problem, combine all available data, and
characterize the various sources of uncertainty associated with
the decision problem [2]. As with any modeling framework, the
results of the analysis depend on the suitability of themodel struc-
ture, the quality of the data inputs, and themethods used to derive
these [3].
The National Institute for Health and Clinical Excellence (NICE,
or the Institute) for England andWales is one of themany national
agencies worldwide that recognize the value of decisionmodels to
inform the assessment of whether or not technologies represent
value for money. The Institute’s guideline for methods of technol-
* Address correspondence to: Pedro Saramago, Centre for Health E
E-mail: pedro.saramago@york.ac.uk.
1098-3015 Copyright © 2012, International Society for Pharmacoec
Published by Elsevier Inc. Open access under CC BY license.ogy appraisal [4] recommends that after defining “. . . explicit cri-
teria bywhich studies are included and excluded . . .” (page 14) “. . .
all relevant evidence . . .” should be “. . . identified, quality as-
sessed and,when appropriate, pooled using explicit criteria . . .” by
means of “. . . justifiable and reproducible methods” (page 27).
One issue typically faced by health economicsmodelers is how
to proceed when multiple sources of evidence are available to in-
form the samemodel input (e.g., relative effectiveness). In the last
decade, there has been a shift toward recognizing the need for a
more systematic identification and utilization of statistical evi-
dence synthesis in decision models [3], at least for effectiveness
parameters, with approaches such as meta-analysis or mixed
treatment comparisons (MTCs) being increasingly used in cost-
effectiveness analysis [5].
Parameters used in decision analytic models, for instance, are
increasingly being estimated from aggregate data available from
published literature. There are, however, several examples where
the model’s parameters have been derived almost exclusively
from a single individual patient-level trial data set [6–10]. Advan-
tages of the latter approach, compared with using aggregate data
only, includemore accurate modeling of the disease’s natural his-
tory and the possibility of exploring heterogeneity in baseline risk
(and/or relative treatment effect) across patient groups. In this
case, the challenge is how to integrate individual patient datawith
any other component of the evidence base thatmay be available in
mics, University of York, Alcuin A, York YO10 5DD, UK.
ics and Outcomes Research (ISPOR).
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640 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 3 9 – 6 4 9aggregate or summary measures format. Methods for combining
multiple individual-level [11] or individual- and aggregate-level
data are rapidly developing [12–16], althoughmany applied health
economics modelers are currently unaware of these.
This article developed a taxonomy based on possible scenarios
typically faced by the analyst when dealing with the evidence
base. Becausemost of themethods development took place in the
area of statistical synthesis of clinical effectiveness measures
fromRCTs, the proposed taxonomy is structured around examples
concerning such parameters (see next section). Statistical ap-
proaches available to synthesize the evidence base under different
scenarios are briefly reported and discussed together with key ref-
erences to full explanations of themethodologies and examples of
where such methods have been used in practice. We make no
claim to be exhaustive with respect to reviewing the various ap-
plications because thiswas not the objective of the article. Instead,
our aim was to use these examples to illustrate and to provide
recommendations regardingwhich techniques aremost appropri-
ate to use to synthesize available information depending on its
format, number of data sources, and number of parameters to be derived.
In addition to applying this taxonomy to clinical effectiveness
parameters, we consider its application to other key economic
model input parameters (in the “Use of Evidence for Other Model
Input Parameters” section) of an economic model including dis-
ease natural history, resource use/costs, and preferences with a
view to discussing issues with the application of the taxonomy to
these other parameters. In doing so, we hope to encourage a fuller
application of this taxonomy to non-effectiveness parameters in
future modeling. Finally, the last section summarizes the main
points of the article and includes suggestions for future research.
A Taxonomy for the Use of Evidence in Cost-
Effectiveness Models: Application to Clinical
Effectiveness Evidence
Good practice in health economic evaluation suggests that deci-
sion models should be structured in a way that appropriately re-
flects the decision problem at hand [17]. The evidence used to
inform themodel inputs often comes from different sources, with
potentially heterogeneous designs (e.g., RCTs, observational, and
expert panels). International health technology assessment stan-
dards in systematic reviews and meta-analysis [18] indicate that
good-quality RCT evidence is the preferred data source for esti-
mating the main clinical effect(s) of interest. There are, of course,
many features of the evidence base (e.g., characteristics of target
population and use of intermediate outcomes rather than final
ones) that may complicate its use for informing a particular eco-
nomic analysis. These are, however, not specific to randomized
data alone. Country-specific health technology assessment guid-
ance documents provide more heterogeneous indications as to
whether or not it is acceptable to use non-randomized evidence to
inform the main clinical effectiveness part of the model in the
absence of evidence from good quality randomized studies [19]. In
the case of NICE for instance, itsmethods guidance states that any
Table 1 – A gallery of scenarios arising when using clinical
Format of data available Single
Single
Aggregate data Scenario A
Individual patient data Scenario C
Mixture of aggregate and individual-level data –limitations of the methods used, potential biases in obtained pa-rameter estimates, caveats about the interpretation of results, and
appropriate reflection of parameter uncertainty should be exten-
sively reported in the analyses submitted for consideration of the
Institute [4]. For simplicity, this article deals with situations in
which the main body of evidence for effectiveness comes from
randomized studies (the added level of complication deriving from
the inclusion of non-randomized data is discussed when relevant
to the argument).
It is arguedhere that the selection of an appropriatemethod for
the analysis and synthesis of clinical effectiveness data for use in
a decision model does depend on three dimensions of the evi-
dence base (listed below), the combination of which gives rise to a
taxonomy of possible scenarios the analyst may face, as illus-
trated in Table 1. These are briefly introduced here and discussed
more fully in the following sections.
Number of available sources of evidence
Depending on the research question, there may be multiple
sources of evidence from randomized trials from which to derive
an estimate of clinical effectiveness, although there are examples
where a single RCT provides the only evidence available.
Formats in which data are available
The above evidence may be available 1) in aggregate form only
(sometimes referred to as summary data), 2) at the individual
level, and 3) in a combination of aggregate- and individual-level
data. Care must be taken when classifying these data formats,
because in some contexts individual-level data may not contain
any extra information beyond what is conveyed by available sum-
mary statistics. For example, basic individual data can be recon-
structed from a summary 2  2 table recording numbers of indi-
iduals at risk and those who experienced a binary outcome in a
wo-arm trial. Either approach will give the same estimate of the
dds ratio (OR) of effect [20]. In this case, the OR is a sufficient
tatistic, in the sense that “. . . no other statistic which can be
alculated from the same sample provides any additional infor-
ation as to the value of the parameter” [21].
Number of (effectiveness) parameters to be derived
It is important to distinguish between the need to synthesize the
evidence to inform a single parameter versus the need to estimate
multiple parameters for use in the decision model (one example
may be the synthesis of the sensitivity and specificity of a diag-
nostic test, another one may be the need to synthesize (one or
more) clinical outcome(s) reported at different time points—most
often these requiring different analytical and evidence synthesis
strategies).
Single source of evidence
Let us start with the simplest scenario of all, that is, where there is
only one single source of evidence from which to derive the pa-
rameter(s) of interest. In this case, the problem is not how to syn-
ence in cost-effectiveness models.
ce of evidence Multiple sources of evidence
ameter Parameter
Multiple Single Multiple
Scenario B1 Scenario A2 Scenario B2
Scenario D1 Scenario C2 Scenario D2
– Scenario E2 Scenario F2evid
sour
Par
1
1thesize the available evidence but how to make the best of this
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nomic model.
Aggregate data to inform the estimation of a single
parameter (A1)
If all the available evidence is in the form of published (summary)
results of a single study, the simplest option is to use these data in
the model “as they are” to inform the derivation of the relevant
parameter estimate in the decision model. For a probabilistic rep-
resentation of these parameters, the analyst will need to have
access to multiple statistics from the source of evidence (e.g.,
mean and standard error). Also, plausibility and sample charac-
teristics (e.g., skewness) may be used to define an appropriate
distribution.
Clearly, exploration of any statistical heterogeneity (i.e., vari-
ability between effect sizes from studies than would be expected
from chance only) relating to a parameter in this circumstance is
unfeasible and usually no further appraisals of the evidence are
possible, other than a simple sensitivity or threshold analysis. At
this stage and in the absence of other source of evidence, the
analyst may want to explore whether attempting to acquire fur-
ther evidence through other techniques (e.g., expert elicitation) is
worth the effort.
Aggregate data to inform the estimation of multiple
parameters (B1)
It is possible for a single published study to provide several inputs
that may be used to derive model parameters. For instance, a sin-
gle (three-arm) trial may provide effectiveness data for a decision
model evaluating the same three alternative treatments. Because
the resulting measures of relative effectiveness (such as ORs or
log-ORs) between these three arms are inherently correlated, it
has been recommended that correlation between parameters
should be explicitly modeled where possible. Failure to do so
would produce not just an incorrect assessment of the uncertainty
in the model but also result in an incorrect estimation of each
treatment’s expected costs and benefits [22–24]. In such instances,
the propagation of correlations is automatic if parameter estima-
tion is conducted in the same program as the decision model
(sometimes called one-step comprehensive decision modeling
[25]) or can be achieved by specifying the full multivariate distri-
butions for the correlated parameters [22]. Methods such as indi-
rect or MTCmodels can be successfully used to address the above
problem (see section B2 and references therein) [4].
Another situation in which it is possible to derive multiple pa-
ameters from a single study occurs when the interest of themod-
ler lies in estimating multiple outcomes/multiple time points on
he same treatment comparison. The range of possible analytical
ptions here may be limited by the lack of information on the
orrelation between outcomes. In some cases, approximate or ad
oc methods may be available to take into account the correlated
ature of the outcomes (e.g., the phi coefficient, Yule’s Q, or Yule’s
—see Epstein and Sutton [24] for further details), and this will
usually be preferable to assuming that the outcomes are indepen-
dent (but less desirable than obtaining the individual data and
estimating the correlations directly).
Individual patient data to inform the estimation of a single
parameter (C1)
Access to individual-level data, especially when there is only one
relevant study forming the evidence base, is particularly advanta-
geous because it allows reanalysis of the data (e.g., inclusion of
further explanatory covariates and conduct of more in-depth
analyses than is possible from summary evidence extracted from
published reports [26]) aimed to derive appropriate model input
parameters. Indeed, compared with the use of summary data, theanalysis of individual data may be considered the most flexible
way to explore and answer clinical and economic research ques-
tions. In this case, data can be analyzed by using the range of
statistical models developed to analyze trial data to estimate the
decision model parameter of interest [27,28]. Given that appropri-
ate methods in this context are extensively documented else-
where, we keep this section brief.
Individual patient data to inform the estimation of multiple
parameters (D1)
The availability of individual-level data often enables the estima-
tion of multiple model parameters. The economic model con-
structed around the third Randomised Intervention Trial of unsta-
ble Angina [10] is an example where the trial data were used to
derive estimate rates of cardiovascular death and myocardial in-
farction (aswell as costs and health-related quality of life) through
regressionmodels applied to a single individual patient-level data
set. As noted in section C1, the possibility to estimate correlations
between correlated input model parameters based on summary
measures is often limited by the data being reported. This is no
longer an issue when one has access to the original study individ-
ual-level data. Another important areawhere access to individual-
level data facilitates the estimation ofmultiple parameters relates
to the analysis of time-to-event data. Because trials’ follow-up are
short in duration [1], to produce long-term estimates of cost-effec-
tiveness most models need to extrapolate the observed trial re-
sults (e.g., fatal and nonfatal events) beyond the trial follow-up.
This can be achieved by employing parametric distributions to
model the outcome of interest. These are typically governed by a
combination of two or more correlated ancillary parameters. Pop-
ular examples of parametric distributions include theWeibull, the
Log-Logistic, and the Generalized Gamma [29] for the analysis of
time-to-event outcomes.
Multiple sources of evidence
There are situations in which the evidence base is represented by
multiple studies. Depending on the format inwhich they are avail-
able and the number of parameters we need to estimate, these
give rise to six possible scenarios (Table 1).
Multiple aggregate data to inform the estimation of a single
parameter (A2)
A typical case occurs when there are several studies reporting
results on the same parameter of interest, and the researcher
needs to combine these into a single quantitative estimate. The
statistical methods most commonly used to achieve such a syn-
thesis fall within the meta-analytic family [30]. In standard meta-
analysis of clinical trials, the parameter of interest is usually some
measure of comparative effectiveness between treatment arms.
A fixed-effect meta-analysis (i.e., assuming that every study is
estimating the same OR, and therefore, only within-study varia-
tion is taken to influence the uncertainty in the results) is carried
out under the assumption that a single common (or “fixed”) effect
underlies every study in the meta-analysis [18]. It is common,
though, to observe between-study variation in treatment effect
estimates (heterogeneous treatment effects). In such a case, it is
customary to use a random effects model (which makes the as-
sumption that while individual studies are estimating different
treatment effects, these come from a common distribution with
some measure of central tendency and some measure of disper-
sion [18]). For an up-to-date comprehensive review of recent de-
velopments inmeta-analysis, the reader can refer to the article by
Sutton and Higgins [31].
Some authors have argued that one of the primeweaknesses of
meta-analysis is a possible failure to control for sources of bias and
that a goodmeta-analysis of badly designed studieswill still result
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dence of suboptimal quality, publication and other related biases
may be present [32].
Study-level features, such as participants’ characteristics,
which may lead to between-study heterogeneity, can be investi-
gated by adopting a meta-regression approach in which study-
level covariates are included in the analysis. Some researchers
would prefer to include “weaker”/“low-quality” studies in the
meta-analysis and add a study-level covariate reflecting themeth-
odological quality of the trials to assess the impact of trial quality
on the effect size. Unfortunately, meta-regression methods also
have a number of weaknesses [33]. The analyst should be aware of
he fact that the use of suchmean study-level covariate values has
ow power (over individual patient data methods) and, more im-
ortantly, carries the risk of “ecological fallacy” (i.e., situations in
hich relationships observed at the aggregate variable level are
ncorrectly inferred to exist also at the individual level) [34] if these
average patient-level characteristics are considered [20,35]. In this
sense, as we shall see in section C2, access to individual data can
be used to disentangle the relationship between the parameter of
interest and baseline covariates [36]. Ades et al. [37] provide an
extensive discussion of how between-study heterogeneity can be
incorporated into the parameters of a decision analytic model
(notice that if the heterogeneity parameter is used to derive pa-
rameters for a decision analyticmodel—technically the analysis is
estimating multiple parameters [i.e., a random-effect estimate of
the treatment effect, its variability, and a measure of heterogene-
ity] and thus belongs to the B2 category).
In cost-effectiveness analysis, the use of estimates of relative
treatment effects derived from a meta-analysis is common [38].
An example of its use within an economic model is the preven-
tion and treatment of influenza A and B [39], where a separate
meta-analysis was conducted to evaluate time to symptoms
alleviated and time to return to normal activities for different
baseline risk groups. In another study, McKenna et al. [40] re-
cently carried out a systematic review and economic evaluation of
the clinical effectiveness and cost-effectiveness of aldosterone an-
tagonists for post–myocardial infarction heart failure. The authors
estimated the effectiveness parameter to inform their cost-effec-
tiveness model by using a Bayesian meta-regression model.
Multiple aggregate data to inform the estimation of multiple
parameters (B2)
Meta-analysis can also be used to achieve more complex forms of
evidence synthesis, to address issues related to multiple (indirect
andmixed treatment) comparisons and combinations of evidence
onmultiple or surrogate/intermediate end points [41]. Much of the
published work on these complex methods of synthesis has been
undertaken within a Bayesian framework, mainly for computa-
tional reasons but also because of its coherent link to decision
making [5]. The term “multiparameter evidence synthesis” (MPES)
adapted fromHasselblad andMcCrory [42] has been coined to des-
ignate these extended methods of synthesis.
When multiple outcomes are of interest, a multivariate meta-
analysis model facilitates the joint estimation of these end points,
thus estimating possible correlation between them. Often, the ad-
vantage of a multivariate random-effects meta-analysis lies in its
ability to use the within-study and between-study correlation of
themultiple end points of interest. For example, Reitsma et al. [43]
have suggested applying a bivariate random-effectsmeta-analysis
to jointly synthesize logit-sensitivity and logit-specificity values
from diagnostic accuracy studies.
More generally, a common feature of the evidence base used to
inform health care funding decisions is the absence of head-to-
head trials comparing all relevant treatment strategies. When
more than two treatments are to be compared and the evidence
base contains different randomized pairwise ormultiarm compar-isons, the appropriate techniques to use in the decision-making
context are indirect treatment comparisons and network meta-
analysis (or MTCs), which are simple extensions of the pairwise
meta-analysis method [44,45]. MTCs can be recognized as an ex-
ample of MPES, in which parameters are related to one another by
a definable structure [46].
In anMTC themodelermay choose between a fixed-effects and
a random-effects analysis depending on the assumptions made
about any between-trial heterogeneity, as discussed in A2 [46,47].
MTC relies on exactly the same assumptions as standard pairwise
meta-analysis (i.e., choice and quality of the studies), although
now these are applicable to the full set of interlinked trials. There-
fore, the similarity between trials included in the networkwill also
be a determinant of the internal validity of the analyses, at the risk
of having a high confounding bias [49]. In the instances where
direct and indirect evidence are combined for a particular compar-
ison, it is also vital that there are no disagreements between the
direct and indirect comparisons (for instance, in an MTC model
comparing three treatments [e.g., A, B, and C], consistency is
achieved when, for each pairwise comparison, no discrepancies can
be found between the direct and indirect estimates of the parameter
of interest [e.g., OR] derived from the model. The issue here is in
defining how big a difference is considered a discrepancy—although
this is arbitrary to define, there are statistical tests [potentially with
reduced power] for discrepancies found) [50–52]. As for standard
meta-analysis, in network meta-analysis it is important to allow for
between-study heterogeneity [53]. An extension of this family of
techniques, allowing for the incorporation of study-level covariates
to explain between-studyheterogeneity and reduce synthesismodel
inconsistency, is also available [53–55].
Details on the use of indirect and MTC for health technology
assessment can be found elsewhere [48]. A good example illustrat-
ing the use of the MTC framework when multiple follow-up times
are available is the article by Lu et al. [56]. For an application of the
MPES approach, the reader is referred to the recent work by Wel-
ton et al. [57], which was originally developed by using data from
the earlier economic appraisal of antiviral treatment by Turner et
al. [39] referred to in A2. Another example where MTCwas used in
an economic analysis can be found in Woolacott et al. [58]. The
authors synthesized clinical effectiveness data from several pub-
lished trials in epilepsy to estimate the transition probabilities
needed to populate a state transition model developed to assess
the cost-effectiveness of alternative medications for epilepsy.
Multiple individual patient data sets to inform the estimation
of a single parameter (C2)
Meta-analysis of individual participant-level data or “mega-anal-
ysis,” where rawdata fromeach study is obtained and synthesized
to inform the estimation of a single parameter of interest, is con-
sidered the “gold-standard” in evidence synthesis [11,59]. This ap-
proachhas a series of advantages,which are summarized by Stew-
art and Tierney [60], Simmonds et al. [61], and Stewart and Parmar
[62]. Access tomultiple individual-level data sets avoids the risk of
bias associated with published aggregate data, allows one to ob-
tain information possibly not available from published reports (or
not available in the format required for the meta-analysis and
cost-effectiveness model), and facilitates consistent inclusion/ex-
clusion criteria to be used across studies [62,63]. An increase in
statistical power to detect true patient-treatment relationships is
gained when compared with meta-regression of summary data
[20,64], which only assesses treatment in relation to group-level
summary data [3]. It should be highlighted that, however, in most
situations, access to individual patient-level trial data may be dif-
ficult due to issues such as confidentiality and sponsors’ or inves-
tigators’ rigidity in releasing this data.
Surprisingly, there is paucity of published literature concern-
ing methodologies for meta-analysis of individual data. Sim-
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using trial-based individual-level data suggesting thatmostmeth-
ods used in practice are straightforward. The review shows that
the majority of applications use a “two-stage” process where ini-
tially each data set is analyzed separately, summary data are
drawn for each study (stage one), and—subsequently—combined
by using a “standard” meta-analytic model for aggregate evidence
(stage two). This approach may be considered a simplification of
the techniques discussed in scenario A2. Alternative and more
robust approaches for dealing with binary [65], ordinal [66], con-
tinuous [11,67], and longitudinal outcomes [68,69] based on ran-
dom-effects generalized hierarchical models exist. Unfortunately,
these approaches appear to be rarely used in practice.
It should be noted that if the outcome of interest is binary and
the analyst does not need to control for covariates (or if the cova-
riates are themselves binary), the information from the summary
data will report the sufficient statistics; that is, no additional benefit
is obtained from access to individual participant-level data (as in
scenario A2).
Multiple individual patient data to inform the estimation of
multiple parameters (D2)
As outlined in section B2, there are clear theoretical and practical
benefits (besides an obvious policy rationale) that justify why it
would be desirable to carry out an MTC (and MPES models in gen-
eral) when deriving parameters for use in cost-effectiveness anal-
ysis. Many of these benefits will also apply when the purpose is to
analyze multiple data sets from which to derive multiple param-
eters for use in decision modeling. Nevertheless, some authors
believe that this need is exacerbated by the fact that an MTC is
essentially an observational study comparing several treatment
strategies. For instance, Salanti et al. [54] point out that while each
individual trial may have high internal validity, studies included
in anMTCwill almost inevitably display between-study variability
in study-level characteristics that can affect the relative effective-
ness of the strategies being compared. One example of this is the
definition of “placebo” or “standard care” in many MTCs [54] and
cost-effectivenessmodels [70], which has been found to vary enor-
mously between studies. Another example is the work by Nixon
et al. [71] and two subsequent cost-effectivenessmodels [72,73], in
which the authors conducted a covariate-adjusted aggregate data
MTC of trial evidence in drugs for rheumatoid arthritis. While this
approach is better than an unadjusted MTC, it still suffers the
same limitations as standard meta-regression. It is therefore es-
sential to carry out a series of tests to assess the consistency of the
evidence in the evidence base network.
Mixture of individual- and aggregate-level data to inform a
single parameter (E2)
When the analyst opts for trying to acquire individual participant
data fromeach relevant study forming the evidence base, themost
frequent scenario he or she encounters is that these data will be
made available only for a subset of the evidence base. In such
situations, analysts have traditionally taken two alternative
routes: 1) include only those studies for which individual data
were available or 2) for the studies where individual data were
available, collapse these to summary evidence and use only the
latter. Neither solution makes optimal use of the available data.
The first option throws away important information, and the sec-
ond ignores all the advantages that individual-level data may
bring toward an improved estimation of the effect size. A better
approachwould be to jointlymodel the individual- and aggregate-
level data [12]. As yet, this issue has not received attention in the
health economics literature, although a series of meta-analysis
models have been recently developed [13–16,74,75] in the statisti-
cal literature specifically for this purpose. These models are valu-able in reducing between-study heterogeneity or in identifying
patient subgroups with differential treatment effects.
Mixture of individual- and aggregate-level data to inform
multiple parameters (F2)
Access to individual-level data (alongside existing aggregate data)
is particularly important when the objective of the evidence syn-
thesis model is the estimation of multiple input parameters to
populate a cost-effectivenessmodel. This is clearly themost tech-
nically challenging scenario the analyst may face, and we are not
aware of the existence of such models yet, despite the scenario
discussed in this section being quite common. In this sense, fur-
ther methodological research aimed at developing models appro-
priate to deal with these situations would be welcome.
An interesting application does exist for diagnostic test evalu-
ation (Riley et al. [13]), with a bivariatemeta-analysis model being
used to model outcomes of diagnostic studies, although this
was not used to inform a cost-effectiveness model. By recon-
structing individual patient-level data from available aggregate
data, the authors manage to take into account the mixture of
individual- and aggregate-level data, which allows for all evi-
dence set to be simultaneously considered in estimating the
parameters of interest (i.e., sensitivity and specificity of the
test). Both individual patient-level data and aggregate data
studies contribute to the estimation of the impact of study-level
covariates and the across-study effects.
For guidance, a summary of the scenarios with corresponding
recommendedmethods and related literature is shown in Table 2.
Use of Evidence for Other Model Input Parameters
While quantitative evidence synthesis methods typically focus on
clinical effectiveness (including adverse events), cost-effective-
ness models require information on many other input parame-
ters, the most important being disease natural progression, cost/
resource use, and (health state) utility data. There are some
examples in the literature where evidence synthesis techniques
have been applied to estimate these parameters. In this section,
we describe the specific characteristics of these parameters and
highlight the implications for methods of synthesis—aiming to
illustrate taxonomy’s applicability.
While clinical effectiveness data used to populate the model
typically come from randomized studies, the evidence base used
to estimate disease natural progression, resource use/cost, and
utility data parameters is often derived from observational evi-
dence (e.g., registries and administrative claim data) [76]. There
are various reasons for this, beyond the fact that RCT evidence
may not be available to populate these model parameters.
First, because of their intrinsic design, randomized data on re-
source use/cost are often considered to have low external validity.
Thismay be because the trial evidence does not reflect true clinical
practice [77] or because the evidence may not be relevant to the
decision-maker for whom the model is being developed [78]. In
this case, observational evidence may provide an opportunity to
calibrate the model parameters and assess the extent to which
trial evidence reflects real-world situations. Methods developed in
the generalized evidence synthesis framework, which facilitate
the synthesis of both randomized and nonrandomized data while
accounting for the different study designs [79,80] and methods
developed for cross-design synthesis [81], may be useful here. We
are not aware of any application of these methods outside the
analysis of clinical effectiveness, and further research in this di-
rection, focusing on parameters such as disease natural history,
could be of great interest. Second, resource use/cost (and to some
extent utility) data are country specific [82], and, in many cases, it
is almost impossible to find jurisdiction-specific RCT evidence on
rios a
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duration. To model disease natural history as well as long-term
costs and utilities, (large) long-term observational studies are of-
ten the only solution. Other specific issues for each type of param-
eter will be discussed in turn in the next subsections.
Disease natural progression data
One of the initial and most important phases in building any de-
cision model is to explicitly define its structure. This entails,
among other things, giving an appropriate representation of the
key health states that the population of interest may experience
over time and reflecting what is known about the natural history
of the particular health condition being modeled as well as the
impact of alternative treatment options on the disease process.
These procedures should be performed in collaboration with both
clinical and nonclinical experts from the field(s) of interest. Ev-
idence about the natural history of a disease is crucial for a good
understanding of possible clinically defined states and, in view
of the complexity of the task, long-term individual data are
ideal for this (detailed individual-level natural history data are
particularly important for modeling the impact that baseline
characteristics may have on parameters in the model that cap-
ture the occurrence of clinical events beyond follow-up and as-
sociated resource use and health-related quality of life). Fur-
thermore, given the concerns about the external validity of
trial-based data evidence, a favored source for baseline risk data
is often case series or high-quality individual-level administra-
tive or epidemiological data sets [85]. Despite relaxing the evi-
dence base inclusion criteria to model disease natural history,
individual-level data are still very often unavailable, leaving
published summary evidence as the only feasible option to in-
form the model parameters.
With respect to the synthesis of data informing the baseline
Table 2 – Scenarios and corresponding current methods lit
effectiveness modeling.
Scenario Source of
evidence
Format of
data
Parameter
A1 Single AD Single Direct
in t
B1 Single AD Multiple Direct
the
C1 Single IPD Single Using
stud
D1 Single IPD Multiple Using
—in
A2 Multiple AD Single Meta-
B2 Multiple AD Multiple Multiv
met
C2 Multiple IPD Single “Mega
D2 Multiple IPD Multiple Multiv
effe
E2 Multiple Mixture Single Two-s
One
usin
F2 Multiple Mixture Multiple Exten
fram
IPD
AD, aggregate data; IPD, individual patient-level data.
* Where there is the need to define uncertain parameters for inclusio
it may be necessary that multiple statistics are reported. Also, it m
distribution best representing the parameter. All subsequent scenahistory part of the model, the publication of a recent useful docu-ment from NICE Decision Support Unit is worth highlighting [86].
This report reviews evidence synthesis issues thatmay arisewhen
dealing with baseline natural history modeling. A discussion of
the source of evidence to use for baseline outcomes, the simulta-
neous versus separatemodeling of baseline and treatment effects,
and the inclusion of covariates in baseline models is provided by
the authors.
Although not presented within an evidence synthesis frame-
work, Isaman and colleagues [87–89] proposed an approach that
allows the use of published regression data to populate a multi-
state model describing disease natural history, even when the
published studymay have ignored intermediary states in themul-
tistate model (taxonomy section B1). The authors applied their
proposed methodology to model several chronic conditions, in-
cluding heart disease and diabetes. Welton and Ades [90], how-
ever, use evidence synthesis methods applied to summary data to
estimate transition probabilities from transition rates, with the
objective of using these tomodel disease progression. The authors
illustrate how to statistically combine data frommultiple sources,
including partially observed data at several follow-up times, to
inform an epidemiologically realistic model (taxonomy section
B2). Chao and Chen [91] recently used a similar approach and de-
veloped a multistate Markov model to predict the progression of
age-related hearing loss, by synthesizing partially observed aggre-
gate data from four studies from which they derived progression
rates (taxonomy section B2).
Modeling disease natural history becomes a lot easierwhen the
analyst has access to individual-level data, and there are many
examples in the literature that show how one can proceed in this
case. Marshall and Jones [92], for instance, developed a multistate
model to describe disease progression in diabetic patients with
retinopathy and used patient-level covariates in themodel to cap-
ture the natural course of the disease and identify the factors as-
re for when using clinical evidence to inform cost-
Methods* Relevant
references
sion of reported estimate (or transformation of it)
del
–
sion of estimates or transformations of them in
l—correlation should be included if reported
[22–24]
ard analysis procedures relevant for the primary [26, 28]
ard multivariate estimation procedures
ng correlations
[10, 60]
sis; Meta-regression [20, 30–33,
35, 37, 39,
62]
e meta-analysis (e.g., bivariate random-effects
lysis); Mixed treatment comparison
[42–46, 48,
50–58]
ysis” (meta-analysis using IPD) [61, 64–66,
68, 69]
e meta-analysis using IPD (e.g., bivariate random-
eta-analysis)
[71]
reduce IPD to AD or reconstruct IPD from AD;
e—hierarchical modeling (e.g., meta-analysis
and IPD)
[12–16, 74,
75]
of previous synthesis models to the hierarchical
rk (e.g., bivariate random-effects meta-analysis of
[13]
decision model and evidence is available as in scenarios A1 and B1,
e of interest to have some information on the characteristics of the
llow for expressions of uncertainty.eratu
inclu
he mo
inclu
mode
stand
y
stand
cludi
analy
ariat
a-ana
-anal
ariat
cts m
tage—
-stag
g AD
sions
ewo
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645V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 3 9 – 6 4 9(taxonomy sectionD1).We are not aware of any applications in the
medical field that, in the presence of multiple patient-level data,
carried out the synthesis of these for the purpose of modeling the
natural history of a disease.
Cost/resource use data
The quantification of the cost of each alternative strategy being
compared is essential for any economic assessment. The best
study design for quantifying health care resource utilization
includes prospective data collection within a long-term natu-
ralistic trial setting. In the absence of these, retrospective anal-
ysis of existing data sets, complemented with examination of
administrative databases, can be an alternative solution. In
fact, it is not uncommon for model parameters associated with
health care resource use to be estimated by reviewing routine
data (e.g., hospital records) [93,94]. Elicitation of expert opinion
95,96] may also play a role in informing the estimates of some
esource use model parameters, although this source of evi-
ence is considered the least preferred, because it usually car-
ies considerable levels of subjectivity.
An article by Bower et al. [95] is one of the few examples in
hich meta-analytic techniques were employed to synthesize
ost data. By using data on costs from trials of counseling in pri-
ary care at the individual participant level, the authors at-
empted to overcome sample size limitations in their economic
nalysis by pooling short- and long-term resource use data from
our different studies using a fixed-effects meta-analysis (taxon-
my sections A2 and B2). This approach has a number of limita-
tions as the authors pointed out (e.g., the significant variation be-
tween trials in SDs of costs and the difficulty in identifying
comparable data and consequently of standardizing cost means),
reinforcing the fact that under no circumstances will the per-
formed analysis approach the precision of primary data collection.
We agree with these conclusions and would argue that while it
is possible to carry out quantitative evidence synthesis of health
care resource use data, there are some real concerns that limit its
validity, over and above the issues mentioned in this section, and
the first of these is technical. Because resource use and costs are
non-normally distributed, their statistical synthesis is particularly
challenging from the analytical point of view, a problem that is
exacerbated when the information is available only at the aggre-
gate study level. Second, there is typically a large methodological
heterogeneity that affects costing studies, which is often impossi-
ble to characterize statistically. Some of the study-level features
that may be responsible for it are differences in data collection
strategies, methods for measuring resource use and costs, fol-
low-up duration, and methods of analysis and reporting. A third
issue relates to time. Technological innovation, relative price
changes, andmany other factors that may affect resource use and
costs are difficult to capture in a synthesis of secondary data.
Health-state utility data
Quality-adjusted life-years are used extensively as a measure of
health benefits in cost-effectiveness analysis for policy decisions
[97]. Their advantage stems from the fact that they combine mor-
bidity andmortality into a single numeraire. Morbidity, for the pur-
pose of quality-adjusted life-year calculation, is measured in
terms of its impact on a preference-based generic measure of
health-related quality of life. Instruments that can be used to es-
timate preference-based generic health-related quality of life in-
clude the EuroQol five-dimensional (EQ-5D) questionnaire [98], the
health utility index [99], the quality of well-being [100], and the
six-dimensional health state short form (SF-6D -derived from
short form 36 health survey) [101]. Several country-specific prefer-
ence weights exist for the EQ-5D questionnaire and SF-6D. The
abundance of alternative instrumentsmeans that researchers andpolicymakers are oftenunclear as towhich of these should be used
and accepted in a given country or jurisdiction. Differences in the
descriptive systems used by each of these instruments generate a
comparability problem [102,103], which is compounded when the
analyst intends to synthesize the available evidence to produce
one parameter estimate of utility for use in themodel. In addition,
disagreement in the literature as to whose preferences should be
used to value health states [104] makes the synthesis even more
complex.
Despite this ongoing debate, the EQ-5D questionnaire has be-
come the most widely used preference-based generic measure of
health-related quality of life in recent years. The increasing inter-
est in the use of this instrument, at least in the UK context, coin-
cided with the publication in 2008 of the third edition of the NICE
methods guidance for technology assessment [4], which indicated
in the EQ-5D questionnaire the instrument of choice for use in the
reference case analyses submitted to the Institute for consider-
ation.
Publicly available repositories of health state utility values for a
variety of health conditions are potentially a very useful data
source. Tengs andWallace [105] were the first to publish a national
repository of 1000 utility values gathered from 154 published re-
ports. More recently, Sullivan and Ghushchyan [106] and Sullivan
et al. [107] used US Medical Expenditure Panel Survey data to de-
velop a prediction tool for preference-based EQ-5D index scores
for chronic conditions in the United States and the United King-
dom based on responders’ International Classification of Diseases,
Ninth Revision codes. These repositories are particularly useful in
the absence of (primary or secondary) preference-based generic
health-related quality-of-life data. When these data are available
and depending on the data’s format and number of parameters to
inform, we have one of the scenarios described in Table 1.
To date, little work has been undertaken on the methods for
statistical synthesis of preference-based health-related quality-
of-life data. This may be because its synthesis is not stated as a
requirement by national bodies such as NICE [4]. Recently, the
NICE Decision Support Unit released a technical support docu-
ment giving guidance on the identification, review, and synthe-
sis of health state utility values [108]. Among a series of recom-
mendations, this document emphasizes the importance of
selecting amain set of relevant utility values, or, in the presence
of multiple relevant values, the pooling of these is suggested to
improve the precision of both mean and variance estimates.
Meta-regression is one of the synthesis methods proposed to
account for variability and to provide support to the choice of
values used.
Perhaps one of the first articles to apply evidence synthesis
methods to health-related quality-of-life data was published by
Kinney et al. [109], who conducted a meta-analysis of 84 studies
reporting summary quality-of-life data in a cardiac patient popu-
lation (taxonomy section A2). Tengs and Lin [110,111] published
meta-regressions in two different clinical areas (i.e., HIV/AIDS and
cardiovascular) with the objective of estimating utility values as-
sociated with specific health states while controlling for specific
study- and instrument-related features (taxonomy section A2). By
using the same methodology, Sturza [112] recently published a
meta-regression of utility values in lung cancer, finding a great
deal of heterogeneity in the data even after applying strict inclu-
sion criteria, and concluded that analysts should avoid direct com-
parisons of lung cancer utility values elicited with dissimilar
methods (taxonomy section A2). Donnan et al. [113] and Cheng
and Niparko [114] found similar problems with respect to combin-
ing utility values froma variety of assessmentmethods. For Cheng
and Niparko [114], it was found to be problematic to do so and “. . .
to some extent, this heterogeneity limits the meaningfulness of
statistical pooling . . .” (page 1217). Other examples of quantitative
evidence synthesis of utility estimates can be found in the litera-
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646 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 3 9 – 6 4 9ture [115–120] (all examples lay within categories A2 and B2 of the
axonomy).
These findings suggest that quantitative synthesis of aggregate
reference-based values is limited by 1) between-study heteroge-
eity in instruments used, 2) the value set used to quantify utili-
ies, and 3) the models used to approximate scores for health
tates; over and above the typical issues related to standardmeta-
egression of summary binary outcome data. It has therefore been
rgued that, particularly in this context, the use of individual pa-
ient-level data would be essential [121].
Further work is required in this area, with regard to both
ethods of quantitative synthesis of heterogeneous prefer-
nce-based outcomes when these are available at aggregate
tudy level and the need to control for between-study hetero-
eneity induced by the use of different preference-based instru-
ents.
Discussion
The information required to carry out economic evaluation stud-
ies for policy decisions often comes from several different data
sources, which often provide multiple estimates of the parame-
ter(s) of interest. Statistical evidence synthesis techniques and de-
cision analytic models represent an ideal vehicle to structure the
decision problem, combine all available data, and characterize the
various sources of uncertainty associated with the decision prob-
lem. By using the synthesis of clinical effectiveness data as a con-
ceptual framework, we developed a taxonomy of possible scenarios
that the analystmay face (and discuss appropriatemethodologies to
use) based on a combination of three factors: 1) the number of data
sources, 2) their format(s), and 3) whether the analyst wishes to de-
rive single or multiple parameters from the synthesis. Recommen-
dations concerning appropriate methods to use under different sce-
narios were provided throughout. This article also reviewed theway
in which evidence has been used to inform decisionmodel parame-
ters related to the disease natural history, costs, and utilities. Areas
where furthermethodological researchmaybeneededare also iden-
tified.
The proposed taxonomy is designed to be used by health eco-
nomics modelers as an instrument to support the development of
their analysis plan, help them to fulfill methodological require-
ments, and adequately address the research question at hand. The
three dimensions on which the taxonomy is based provide a sim-
ple method of characterizing and categorizing the evidence base
available (i.e., in terms of its quantity and format) linking this to
the (type and number of) decision model parameter(s) to be de-
rived. Following this “checklist,” the analyst can easily identify
within the relevant taxonomy cell (or cells)methods that are avail-
able and those that are recommended. This list of approaches and
methods has been (wherever possible) supported by references to
key methods literature and case studies where these have been
put into practice. The references can then be consulted by analysts
in search of further methodological and/or practical details of the
subject. In this sense, the taxonomy helps to ensure consistency
and completeness when carrying out the task of using evidence to
inform decision models, standardizing approaches, and the ade-
quate use ofmethods to analyze/synthesize evidence. In addition,
it provides a useful reference on the more recent methodological
developments in the context of evidence synthesis for health care
cost-effectiveness analysis.
The current taxonomy foundations are not, however, without
limitations. First, the evidence synthesis methodologies and ap-
plied studies described throughout the article are not the result of
a comprehensive systematic review (i.e., not exhaustive). We be-
lieve, however, that these are representative of themethodologies
found in the methods and applied literature in this area of re-
search. Second, despite our efforts to make this taxonomy easy togeneralize, the three dimensions (number and format of data
sources andnumber of parameters to inform)may still not capture
all possible scenarios. For instance, the taxonomy could be ex-
tended to include extra dimensions—for example, extrapolation
ofmodel estimates—or detailed to cover other aspects—for exam-
ple, role of covariates within each taxonomy section. It was felt,
however, that such an extension would unnecessarily increase its
complexity without adding substantial benefits.
Finally, the taxonomy is applied to clinical effectiveness but
not to other key economic model parameters (i.e., disease natural
history, resource use/costs, and preferences). Nonetheless, issues
relating to the application of the taxonomy to these other param-
eters are discussed and its fuller application encouraged in future
research. Methodological and applied literature is scarce regard-
ing the quantitative synthesis of evidence to inform these—we
believe that further research is required despite recent relevant
contributions in this area [86,108]. Moreover, the specific charac-
teristics of these parameters and of the evidence used to inform
them may pose further challenges. Some of these evidence char-
acteristics are highlighted and discussed next.
In practice, studies included in a certain synthesis may vary in
their degree of rigor and possibly in their relevance toward the
research question. This is particularly important when “relevant”
available evidence comes from observational data. Flaws in the
design or conduct of a study can result in bias, and in some cases
this can have as much influence on observed effects as that of the
treatments. Important intervention effects, or lack thereof, can be
obscured by bias. Assessment of study quality gives an indication
of the strength of evidence provided by the pooled result and ulti-
mately, quality assessment helps to answer the question of
whether included studies are sufficiently robust to guide treat-
ment, prevention, diagnostic, or policy decisions. Most of the bias
adjustment proposals published so far are reweighting schemes,
usually attributing lower weight to evidence with a high risk of
bias. More information on this topic can be found in Spiegelhalter
and Best [80], Turner et al. [122], and Welton et al. [123].
Common to all evidence identified, to potentially inform deci-
sionmodel parameters, is the case of partial reporting of informa-
tion. If, for instance, mean differences without a measure of vari-
ance are reported, difficulties may arise when attempting to
parameterize data for probabilistic modeling and strong assump-
tions may have to be imposed. A variety of methods for imputing
variances have been proposed—see Abrams et al. [124], Wiebe et
al. [125], and Furukawa et al. [126] for further details. Another ex-
ample occurs when different studies report different (multiple)
outcomemeasures, at different time points and possibly on differ-
ent scales. All these issues raise important obstacles for the syn-
thesis of evidence.
A number of authors have recently published articles relating
to the synthesis of cost-effectiveness model outputs [127–133].
One of the key questions here is whether or not it is appropriate to
do so. In our view, there is no apparent rationale for assuming that
the costs of a particular health care intervention (or their health
utilities) estimated in different studies carried out in different
countries and health care settings, probably using different mea-
surement and assessment instruments, should converge toward a
common value to be estimated by using evidence synthesis tech-
niques [131].
Conclusions
This article brings recent developments in quantitative evidence
synthesis to the attention of the health economics modeling com-
munity, encouraging a broader andmore explicit consideration of
these methods in the future. Several of the techniques presented
here fall in the spheres of epidemiology, statistics, and operational
research, which in some cases are not directly accessible (because
647V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 3 9 – 6 4 9of lack of exposure and increased complexity of methods) to
health economics modelers.
The taxonomy should be viewed by readers/analysts as a sup-
plement to the guidelines on methods for technology assessment
published by NICE [4] and increase the users’ confidence sur-
rounding the validity of decision model inputs and subsequent
outputs.
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